Loading…

DNMT1 Deficiency Impacts on Plasmacytoid Dendritic Cells in Homeostasis and Autoimmune Disease

Dendritic cells (DCs) are heterogeneous immune regulators involved in autoimmune diseases. Epigenomic mechanisms orchestrating DC development and DC subset diversification remain insufficiently understood but could be important to modulate DC fate for clinical purposes. By combining whole-genome met...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of immunology (1950) 2022-01, Vol.208 (2), p.358-370
Main Authors: Czeh, Melinda, Stäble, Sina, Krämer, Stephen, Tepe, Lena, Talyan, Sweta, Carrelha, Joana, Meng, Yiran, Heitplatz, Barbara, Schwabenland, Marius, Milsom, Michael D, Plass, Christoph, Prinz, Marco, Schlesner, Matthias, Andrade-Navarro, Miguel A, Nerlov, Claus, Jacobsen, Sten Eirik W, Lipka, Daniel B, Rosenbauer, Frank
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dendritic cells (DCs) are heterogeneous immune regulators involved in autoimmune diseases. Epigenomic mechanisms orchestrating DC development and DC subset diversification remain insufficiently understood but could be important to modulate DC fate for clinical purposes. By combining whole-genome methylation assessment with the analysis of mice expressing reduced DNA methyltransferase 1 levels, we show that distinct DNA methylation levels and patterns are required for the development of plasmacytoid DC and conventional DC subsets. We provide clonal in vivo evidence for DC lineage establishment at the stem cell level, and we show that a high DNA methylation threshold level is essential for Flt3-dependent survival of DC precursors. Importantly, reducing methylation predominantly depletes plasmacytoid DC and alleviates systemic lupus erythematosus in an autoimmunity mouse model. This study shows how DNA methylation regulates the production of DC subsets and provides a potential rationale for targeting autoimmune disease using hypomethylating agents.
ISSN:0022-1767
1550-6606
1550-6606
DOI:10.4049/jimmunol.2100624